NASDAQ · Biotechnology
Intellia Therapeutics Inc (NTLA)
$10.00
+5.04%
37
In band
Moving averages
SMA 200$13.01-23.14%
Company profile
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
SectorHealthcare
IndustryBiotechnology
Market cap$1.60B
P/E ratioNone
EPS$-3.35
Beta1.821
Dividend yield0.00%
52-week high$18.48
52-week low$7.95
Similar stocks in Biotechnology
BNTX
BioNTech SE
RSI 32
VRTX
Vertex Pharmaceuticals Inc
RSI 43
CRSP
CRISPR Therapeutics AG
RSI 27
IOVA
Iovance Biotherapeutics Inc
RSI 31
NVAX
Novavax Inc
RSI 33
GPCR
Structure Therapeutics Inc
RSI 25
SRPT
Sarepta Therapeutics Inc
RSI 29
GHRS
GH Research PLC
RSI 41
MRVI
Maravai LifeSciences Holdings Inc - Class A
RSI 48
ANRO
Alto Neuroscience Inc
RSI 52
RSI alerts for NTLA
An email when NTLA closes below RSI 30 or above 70. Nothing else.
Data last updated 13 November 2026 at 4:40 AM EST